|Project Title||Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study|
Tuesday, June 7, 2016
Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents. Objective: To examine the associations of hHF with saxagliptin and sitagliptin.
- Vaccines, Blood & Biologics
- Devices and Radiologic Health